Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Trials |
| Online Access: | https://doi.org/10.1186/s13063-022-06972-9 |
| _version_ | 1828265274813448192 |
|---|---|
| author | Nathan R. Hill Daniel Lasserson Ben Thompson Rafael Perera-Salazar Jane Wolstenholme Peter Bower Thomas Blakeman David Fitzmaurice Paul Little Gene Feder Nadeem Qureshi Maarten Taal Jonathan Townend Charles Ferro Richard McManus F. D. Richard Hobbs |
| author_facet | Nathan R. Hill Daniel Lasserson Ben Thompson Rafael Perera-Salazar Jane Wolstenholme Peter Bower Thomas Blakeman David Fitzmaurice Paul Little Gene Feder Nadeem Qureshi Maarten Taal Jonathan Townend Charles Ferro Richard McManus F. D. Richard Hobbs |
| author_sort | Nathan R. Hill |
| collection | DOAJ |
| first_indexed | 2024-04-13T04:37:00Z |
| format | Article |
| id | doaj.art-881d5faeee0b45829ab789f7171b3220 |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-04-13T04:37:00Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-881d5faeee0b45829ab789f7171b32202022-12-22T03:02:08ZengBMCTrials1745-62152022-12-012311210.1186/s13063-022-06972-9Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R. Hill0Daniel Lasserson1Ben Thompson2Rafael Perera-Salazar3Jane Wolstenholme4Peter Bower5Thomas Blakeman6David Fitzmaurice7Paul Little8Gene Feder9Nadeem Qureshi10Maarten Taal11Jonathan Townend12Charles Ferro13Richard McManus14F. D. Richard Hobbs15Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterDepartment of Public Health, University of OxfordCentre for Primary Care, Institute of Population Health, University of ManchesterCentre for Primary Care, Institute of Population Health, University of ManchesterPrimary Care Clinical Sciences, School of Health and Population Sciences, College of Medical and Dental Sciences, University of BirminghamPrimary Medical Care, University of Southampton, Aldermoor Health CentreSchool of Social and Community Medicine, University of BristolSchool of MedicineDepartment of Renal Medicine, Royal Derby HospitalCardio-Renal Research Group, Departments of Cardiology and Nephrology, Queen Elizabeth Hospital Birmingham and University of BirminghamCardio-Renal Research Group, Departments of Cardiology and Nephrology, Queen Elizabeth Hospital Birmingham and University of BirminghamNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory QuarterNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarterhttps://doi.org/10.1186/s13063-022-06972-9 |
| spellingShingle | Nathan R. Hill Daniel Lasserson Ben Thompson Rafael Perera-Salazar Jane Wolstenholme Peter Bower Thomas Blakeman David Fitzmaurice Paul Little Gene Feder Nadeem Qureshi Maarten Taal Jonathan Townend Charles Ferro Richard McManus F. D. Richard Hobbs Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial Trials |
| title | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_full | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_fullStr | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_full_unstemmed | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_short | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_sort | correction benefits of aldosterone receptor antagonism in chronic kidney disease barack d trial a multi centre prospective randomised open blinded end point 36 month study of 2 616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone study protocol for a randomized controlled trial |
| url | https://doi.org/10.1186/s13063-022-06972-9 |
| work_keys_str_mv | AT nathanrhill correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT daniellasserson correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT benthompson correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT rafaelpererasalazar correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT janewolstenholme correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT peterbower correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT thomasblakeman correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT davidfitzmaurice correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT paullittle correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT genefeder correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT nadeemqureshi correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT maartentaal correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT jonathantownend correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT charlesferro correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT richardmcmanus correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT fdrichardhobbs correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda |